Singular Genomics is an early-stage life science tools company developing next-generation DNA sequencing (NGS) instruments and spatial biology platforms. Singular's core commercial product is the G4 Sequencing Platform, a benchtop NGS instrument that sequences DNA and RNA for applications including single-cell RNA sequencing, whole genome sequencing, and targeted panels. The G4's main selling points are speed (single-day run times), flexibility via four independent flow cells, and accuracy. Singular sells directly to academic core labs, research institutions, biopharma and biotech companies, and commercial labs, primarily in North America with limited European presence. Singular follows a razor/razor-blade model: instruments are sold outright or placed via reagent rental arrangements, with recurring revenue coming from consumable flow cell kits sold per sequencing run. Instrument margins are thin or negative at current volumes; consumables carry higher margins and are the long-term earnings driver. Singular's emerging priority is the G4X Spatial Sequencer, currently in development and entering early access. The G4X sequences RNA directly within cells and tissue while simultaneously profiling proteins and staining from the same tissue section, with throughput the company claims leads the industry. The G4X is designed to share the G4 platform, enabling existing G4 customers to upgrade. Kit economics on the G4X are expected to be materially better than the G4, given higher samples-per-run and higher per-run pricing. Singular is pre-profitability and has pivoted R&D and commercial resources heavily toward the G4X, while reducing headcount to extend cash runway.